Smith & Nephew Stock - Q1 2026 growth and $500 million buyback

Smith & Nephew stock is underpinned by a solid first-quarter 2026 trading update and a new $500 million share buyback. Growth was led by Sports Medicine, while management kept its full-year outlook unchanged.

Edited by ad hoc news Chart & Technicals Desk. Verified prior to publication on 06/18/2026, 18:39 CET. Details in the imprint.

Smith & Nephew (GB0009223206) reported underlying revenue growth for the first quarter of 2026 and confirmed a new $500 million share buyback, according to its trading update dated 05/06/2026. The update also reiterated the company’s full-year guidance and pointed to solid Sports Medicine momentum.

What the Q1 update showed

In its first quarter 2026 trading update, Smith & Nephew reported revenue of $1,501 million, up 6.6% on a reported basis and 3.1% on an underlying basis. On an adjusted daily sales basis, underlying growth reached 4.7%, reflecting one more trading day in the quarter.

The company highlighted strong performance in Sports Medicine, which helped offset a softer showing in US Knee Implants. Management described the quarter as in line with expectations and said the performance supported keeping the full-year outlook unchanged.

The trading statement also confirmed that results for the second quarter and first half of 2026 are scheduled for release on 08/04/2026. An analyst conference call on the Q1 figures was held on 05/06/2026 at 8:30 a.m. BST, emphasizing investor interest in execution on the group’s strategic priorities.

Buyback and chart picture on Thursday

Alongside the Q1 update, Smith & Nephew announced a new $500 million share buyback program, to be executed over the twelve months following the release. The company framed the buyback as part of disciplined capital allocation, supported by its balance sheet and cash generation.

On the London Stock Exchange, Smith & Nephew shares most recently traded at GBX 1,131, with an intraday range between GBX 1,126 and GBX 1,139.50 on 06/18/2026. That level leaves the stock broadly stable compared with the prior close, according to price data from Davy.

Seen over recent months, the share price has been consolidating below the average analyst target of about GBX 1,383, based on MarketBeat data for eight covering analysts. The consensus rating stands at "Hold", reflecting a mixed but cautious stance on near-term upside.

The business behind the stock

Smith & Nephew specializes in medical devices, with three main franchises: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. Its portfolio includes hip and knee implants, sports-injury repair systems, and advanced dressings for complex wounds.

Where the stock trades today

Smith & Nephew shares (GB0009223206) trade on the London Stock Exchange at GBX 1,131.00 as of 06/18/2026, 02:20 BST.

Key facts on Smith & Nephew stock

• Company: Smith & Nephew plc
• ISIN: GB0009223206
• WKN: 922320
• Ticker: SN
• Venue: London Stock Exchange
• Price (as of 06/18/2026, 02:20 BST): 1,131.00 GBX
• Market cap: 9,88 billion GBP (as of 06/18/2026)
• Sector / Industry: Health Care / Medical Devices
• Index membership: FTSE 100
• Next earnings date: 08/04/2026

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.